ST
INSY

Spot Trading’s Insys Therapeutics, Inc. INSY Stock Holding History

Spot Trading’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,300
Closed -$54K – 3532
2017
Q2 		$54K Buy
4,300
+3,800
+760% +$45K ﹤0.01% 2796
2017
Q1 		$5K Buy
+500
New +$5.33K ﹤0.01% 2805
2016
Q2 		– Sell
-43,400
Closed -$694K – 4035
2016
Q1 		$694K Buy
+43,400
New +$824K 0.01% 1344

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Spot Trading's INSY Position: Q2 2016 in Review

Spot Trading sold out of Insys Therapeutics, Inc. (INSY) in Q2 2016, closing a stake of 4,361 shares — an estimated $70K sold.

Spot Trading first reported a position in INSY in Q3 2014 and held it in 4 quarters. The position peaked at $70K in Q1 2016. 124 funds tracked by Wall St. Rank hold INSY as of Q2 2016.

  • Spot Trading reported no remaining Insys Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Spot Trading sold 4,361 Insys Therapeutics, Inc. shares in Q2 2016, an estimated $70K.
  • Spot Trading first reported a position in Insys Therapeutics, Inc. in Q3 2014 and held it in 4 quarters.
  • Spot Trading's Insys Therapeutics, Inc. position peaked at $70K in Q1 2016.
  • 124 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2016.

Based on Spot Trading's 13F filing for Q2 2016, filed 2 Aug 2016.